Sangamo Therapeutics files for Chapter 11 as Lilly, Astellas anchor asset sale bids

Sangamo Therapeutics, Inc.

SGMO

0.00

Sangamo Therapeutics filed for voluntary Chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware.
Process targets a court-supervised auction of substantially all assets, with sales expected to run under Section 363.
Lilly signed a stalking-horse deal for key technology platforms and the ST-506 prion disease program.
Astellas signed a stalking-horse deal for the ST-920 Fabry disease gene therapy program.
DIP financing commitment secured from Northridge ATM to support operations during the Chapter 11 process, subject to court approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sangamo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606230805PRIMZONEFULLFEED9751019) on June 23, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.